Program
Anti-FAP Antibody-drug Conjugate OMTX705
Its studies are led by Oncomatryx Biopharma S.L.
Furthest: phase 1, since Jun 2, 20222 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Oncomatryx Biopharma S.L. | 22 open or running | phase 1since Jun 2, 2022 | Jun 2, 2022 | Dec 2027phase 1 · NCT05547321 |
Also a collaborator on its studies: Certara, Biotrial and Clinigen.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 2, 2022First study: phase 1 study in Advanced Solid TumorFirst studyNCT05547321 · 150 planned · United States, Spain
- Dec 1, 2025Phase 1 study in Pancreatic Adenocarcinoma MetastaticNCT07377045 · 69 planned · United States, Spain
Ahead
- Dec 2027Primary completion: phase 1 study in Advanced Solid TumorNCT05547321
- Mar 2029Primary completion: phase 1 study in Pancreatic Adenocarcinoma MetastaticNCT07377045
TargetBeta
FAP →read by rule
“An antibody-drug conjugate (ADC) composed of OMTX005, a humanized monoclonal antibody directed against fibroblast activation protein (FAP), ”NCIt, by rule
Other programs on FAP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Fluorine F 18 FAPI-74rule | sofie | phase 3 | 3 |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 1 |
| HRS-6768 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Gallium Ga 68 NNS309 | Novartis | phase 1 | 2 |
| Actinium Ac 225 RTX-2358rule | ratio-therapeutics-inc | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050rule | Immunome | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07377045Pancreatic Adenocarcinoma Metastatic · United States, Spain | 1 | Recruiting | Mar 2029 | 69 |
| NCT05547321Advanced Solid Tumor · United States, Spain | 1 | Recruiting | Dec 2027 | 150 |
How it is read
Names in the registry
- “OMTX705”, 6 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.